These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Letter: intrauterine prostaglandins for outpatient termination of very early pregnancy.
    Author: Karim SM.
    Journal: Lancet; 1973 Oct 06; 2(7832):794. PubMed ID: 4126492.
    Abstract:
    The efficacy of PGs (prostaglandins) in terminating human pregnancy has been repeatedly demonstrated. The disadvantages associated with systemic administration of PGs can be overcome by use of other routes of administration. Single intraamniotic injections of PGE2 or PGF2alpha will cause 2nd-trimester terminations in most cases. PGs used for 1st-trimester procedures have proven unsuccessful due to the high rate of incomplete abortions produced. An ideal fertility control method would be self-administration of PGs during very early pregnancy. Vaginal administration of PGs has produced high rates of side effects and extrauterine PG administration has required repeated dosing, too much time, and hospital admission. Recent experimentation was carried out using PGE2 or PGF2alpha administered via the cervix into the uterine cavity. A single dose of 1 mg PGE2 or 4 mg PGF2alpha gave the most consistent results, onset of bleeding within 2-5 hours and a negative pregnancy test within 14 days. Higher doses of either substance caused severe gastric side effects. Clinical trials with larger groups are needed to confirm the study findings.
    [Abstract] [Full Text] [Related] [New Search]